Medicamen Biotech
- Market cap
- ₹ 349 Cr.
- P/E
- 33x
- P/B
- 1.31x
- 52-week range
- 212.4 – 447.65
- ROE
- 4%
- ROCE
- 5%
- Dividend yield
- 0.4%
- Debt / equity
- 0.18
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider. The Company is principally engaged in generic finished dosage forms (FDF), Oncology formulations and research and development services to cater to the needs of the global pharmaceutical industry. The Company’s focus areas include antibiotics, hypertension, general pain management, cardiovascular, diabetics and oncology formulations. In cardiology, the Company is delivering effective treatments for heart-related conditions. Its CNS products address neurological disorders, while its diabetology solutions focus on advanced diabetes management. It also contributes to the global fight against malaria with its anti-malarial medications. Additionally, the Company offers essential vitamins, antibiotics for bacterial infections, and comprehensive pain management solutions. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Medicamen Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)33 against a typical 34.3: cheaper than most peers (1st = cheapest).107th of 220
- Sales growth+11.3% against a typical +15.6% from a year earlier.111th of 197
- Profit growth+15.6% against a typical +18.9% from a year earlier.90th of 160
- Share price, 3 months+13.3% against a typical 0%.54th of 200
- Size₹ 349.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).106th of 199
Latest announcements
Exchange filings and their impact on the company.
- Promoter infused Rs 26.5 cr via warrant conversion, lifting net worth ~10% with ~3.7% dilution.
Medicamen Biotech allotted 5,00,000 equity shares at Rs 530 each on conversion of warrants to promoter-group entity Shivalik Rasayan, raising Rs 26.5 crore. Paid-up capital rose to Rs 14.06 crore comprising 1,40,62,815 shares of Rs 10 each. The promoter infusion strengthens the balance sheet with modest dilution.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB- by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil BBB- | Stable | 1 Dec 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 1 Dec 2025 | Reaffirmed | Crisil BBB- | — | CRISIL | ₹ 42 Cr. |
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 23 Oct 2026 | Warrant conversion | Allotted | ₹ 26.5 Cr. | ₹ 530 | −49.63% |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 27 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 30 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 44 | 47 | 47 | 43 | 45 | 45 | 30 | 43 | 47 | 47 | 61 | 48 |
| Expenses | 39 | 42 | 42 | 40 | 39 | 38 | 31 | 38 | 42 | 43 | 55 | 44 |
| Operating Profit | 5 | 5 | 6 | 3 | 5 | 7 | −2 | 5 | 5 | 4 | 5 | 4 |
| OPM % | 10.7% | 10.5% | 12.2% | 8% | 11.9% | 14.9% | −5.4% | 10.7% | 10.9% | 9.3% | 9% | 9% |
| Other Income | 1 | 1 | 1 | 1 | 0 | 0 | 5 | 0 | 0 | 1 | 2 | 1 |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 3 | 2 | 0 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 3 | 2 | 5 | 3 |
| Tax % | 39.7% | 38.1% | 22.9% | 48.7% | 53.9% | 24.7% | 25.3% | 24.9% | 21.3% | 22.3% | 12.1% | 28.4% |
| Net Profit | 1 | 2 | 2 | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 4 | 2 |
| EPS in Rs | 1.19 | 1.9 | 1.68 | 1.06 | 1.15 | 2.73 | 1.9 | 1.59 | 1.97 | 1.61 | 2.85 | 1.56 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 12%
- 3 Years
- 12%
- TTM
- 25%
- 10 Years
- —
- 5 Years
- −4%
- 3 Years
- −13%
- TTM
- 14%
- 10 Years
- 3%
- 5 Years
- −17%
- 3 Years
- −31%
- TTM
- —
- 10 Years
- —
- 5 Years
- 6%
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Medicamen Biotech | ₹ 266.95 | ₹ 349 Cr. | 33x | 1.3x | 4% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Rajesh Madan
- Chief Executive Officer
- Chandan Kumar
- Chief Financial Officer
- Parul Choudhary
- Compliance Officer, Company Secretary
- Ashwani Kumar Sharma
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.